Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.64 |
| ▸ | CTSS | P25774 | 5/20 | 0.61 |
| ▸ | CTSB | P07858 | 4/20 | 0.61 |
| ▸ | CTSK | P43235 | 3/20 | 0.61 |
| ▸ | CTSH | P09668 | 1/20 | 0.61 |
| ▸ | CTSC | P53634 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028082 | 1.00 | CTSL (0.64) | CTSLCTSSCTSBCTSKCTSH | |
| SCHEMBL7028841 | 1.00 | CTSL (0.64) | CTSLCTSSCTSBCTSKCTSH | |
| SCHEMBL7024509 | 0.90 | CTSS (0.75) | CTSLCTSSCTSBCTSKCTSH | |
| SCHEMBL7026009 | 0.90 | CTSS (0.75) | CTSLCTSSCTSBCTSKCTSH | |
| SCHEMBL7025999 | 0.90 | CTSS (0.75) | CTSLCTSSCTSBCTSKCTSH | |
| SCHEMBL7024515 | 0.90 | CTSS (0.75) | CTSLCTSSCTSBCTSKCTSH | |
| SCHEMBL7028107 | 0.90 | CTSL (0.78) | CTSLCTSSCTSB | |
| SCHEMBL7028114 | 0.90 | CTSL (0.78) | CTSLCTSSCTSB | |
| SCHEMBL7028122 | 0.90 | CTSL (0.78) | CTSLCTSSCTSB | |
| SCHEMBL7133138 | 0.85 | CTSS (0.57) | CTSLCTSSCTSBCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002048097-A9 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INT INC (US) | 2003-05-08 | — | — | WO | claimed |
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | DENDREON CORPORATION | 2002-08-08 | — | — | US | claimed |
| WO-2002048097-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INTERNATIONAL, INC. (US) | 2002-06-20 | — | — | WO | claimed |
| WO-2002048097-A9 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INT INC (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | DENDREON CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2002048097-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INTERNATIONAL, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | CAT, CTSA, CTRL | CTSL 26/4885CTSS 5/4885CTSB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.